Login to Your Account



Pharma: Clinic Roundup


Tuesday, February 28, 2012
• Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, reported Phase II data showing that TAK-875, a GPR40 agonist, met its primary endpoint of statistically significantly lowering HbA1c levels over a 12-week period vs. placebo in Type II diabetes patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription